On the contrary, high expression of each of nine genes (poor prognosis: MARS2, AHCY, SRM, DNMT1, MTR, MTAP, DNMT3A, CBS, AMD1; good prognosis: MAT2B) was significantly associated with the prognosis of neuroblastoma patients and five (poor prognosis: AHCY, CBS, DNMT3A, DNMT3B, MTAP; good prognosis: MAT2B) for breast cancer patients (Figure 4b). This evidence concerns the gene MAT2B and neuroblastoma.